Ixabepilone: Antimitotic drug microtubule-stabilizing agent epothilone

Sridhar Mani, Mohammed Ghalib, Sanjay Goel, N. Serradell, J. Bolós, E. Rosa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Ixabepilone (BMS-247550, Ixempra™) is an analogue of epothilone B that exerts antitumor activity by stabilizing microtubules. The epothilones were originally isolated from a fermentation of a myxobacteria, Sorangium cellulosum, and later synthesized. These natural products were shown to bind to tubulin, stabilize microtubules and induce mitotic arrest at the G2/M transition, resulting in potent anticancer activity, especially against taxane-resistant tumors. Ixabepilone was recently approved by the FDA as monotherapy for resistant or refractory metastatic or locally advanced breast cancer. Phase III clinical development for the treatment of breast cancer continues, as well as earlier clinical trials for many other types of solid tumors and hematological malignancies.

Original languageEnglish (US)
Pages (from-to)1033-1039
Number of pages7
JournalDrugs of the Future
Volume32
Issue number12
DOIs
StatePublished - Dec 2007

Fingerprint

Epothilones
Antimitotic Agents
Excipients
Microtubules
Myxococcales
Breast Neoplasms
Hematologic Neoplasms
Tubulin
Biological Products
Fermentation
Neoplasms
Clinical Trials
ixabepilone
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Ixabepilone : Antimitotic drug microtubule-stabilizing agent epothilone. / Mani, Sridhar; Ghalib, Mohammed; Goel, Sanjay; Serradell, N.; Bolós, J.; Rosa, E.

In: Drugs of the Future, Vol. 32, No. 12, 12.2007, p. 1033-1039.

Research output: Contribution to journalArticle

Mani, Sridhar ; Ghalib, Mohammed ; Goel, Sanjay ; Serradell, N. ; Bolós, J. ; Rosa, E. / Ixabepilone : Antimitotic drug microtubule-stabilizing agent epothilone. In: Drugs of the Future. 2007 ; Vol. 32, No. 12. pp. 1033-1039.
@article{8cffc08a0e5749c0bf7f1fb8a7b0efa1,
title = "Ixabepilone: Antimitotic drug microtubule-stabilizing agent epothilone",
abstract = "Ixabepilone (BMS-247550, Ixempra™) is an analogue of epothilone B that exerts antitumor activity by stabilizing microtubules. The epothilones were originally isolated from a fermentation of a myxobacteria, Sorangium cellulosum, and later synthesized. These natural products were shown to bind to tubulin, stabilize microtubules and induce mitotic arrest at the G2/M transition, resulting in potent anticancer activity, especially against taxane-resistant tumors. Ixabepilone was recently approved by the FDA as monotherapy for resistant or refractory metastatic or locally advanced breast cancer. Phase III clinical development for the treatment of breast cancer continues, as well as earlier clinical trials for many other types of solid tumors and hematological malignancies.",
author = "Sridhar Mani and Mohammed Ghalib and Sanjay Goel and N. Serradell and J. Bol{\'o}s and E. Rosa",
year = "2007",
month = "12",
doi = "10.1358/dof.2007.032.12.1157611",
language = "English (US)",
volume = "32",
pages = "1033--1039",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "12",

}

TY - JOUR

T1 - Ixabepilone

T2 - Antimitotic drug microtubule-stabilizing agent epothilone

AU - Mani, Sridhar

AU - Ghalib, Mohammed

AU - Goel, Sanjay

AU - Serradell, N.

AU - Bolós, J.

AU - Rosa, E.

PY - 2007/12

Y1 - 2007/12

N2 - Ixabepilone (BMS-247550, Ixempra™) is an analogue of epothilone B that exerts antitumor activity by stabilizing microtubules. The epothilones were originally isolated from a fermentation of a myxobacteria, Sorangium cellulosum, and later synthesized. These natural products were shown to bind to tubulin, stabilize microtubules and induce mitotic arrest at the G2/M transition, resulting in potent anticancer activity, especially against taxane-resistant tumors. Ixabepilone was recently approved by the FDA as monotherapy for resistant or refractory metastatic or locally advanced breast cancer. Phase III clinical development for the treatment of breast cancer continues, as well as earlier clinical trials for many other types of solid tumors and hematological malignancies.

AB - Ixabepilone (BMS-247550, Ixempra™) is an analogue of epothilone B that exerts antitumor activity by stabilizing microtubules. The epothilones were originally isolated from a fermentation of a myxobacteria, Sorangium cellulosum, and later synthesized. These natural products were shown to bind to tubulin, stabilize microtubules and induce mitotic arrest at the G2/M transition, resulting in potent anticancer activity, especially against taxane-resistant tumors. Ixabepilone was recently approved by the FDA as monotherapy for resistant or refractory metastatic or locally advanced breast cancer. Phase III clinical development for the treatment of breast cancer continues, as well as earlier clinical trials for many other types of solid tumors and hematological malignancies.

UR - http://www.scopus.com/inward/record.url?scp=41549101102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549101102&partnerID=8YFLogxK

U2 - 10.1358/dof.2007.032.12.1157611

DO - 10.1358/dof.2007.032.12.1157611

M3 - Article

AN - SCOPUS:41549101102

VL - 32

SP - 1033

EP - 1039

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 12

ER -